Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non-Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?
- School of Medicine, Yamanashi University, Yamanashi (Japan)
- School of Medicine, Hokkaido University, Sapporo (Japan)
- School of Medicine, Hiroshima University, Hiroshima (Japan)
- School of Medicine, Kyoto University, Kyoto (Japan)
- Cancer Institute Suwa Red-Cross Hospital, Suwa (Japan)
- Tokyo Metropolitan Komagome Hospital, Tokyo (Japan)
- Kitasato University, Kanagawa (Japan)
- School of Medicine, Hirosaki University, Hirosaki (Japan)
- School of Medicine, Kagawa University, Hiroshima (Japan)
- Ofuna Chuo Hospital, Kanagawa (Japan)
- Keijinkai Hospital, Sapporo (Japan)
- Sapporo Medical University, Sapporo (Japan)
- Institute of Biomedical Research and Innovation, Kobe (Japan)
- School of Cancer Institute Ariake Hospital, Tokyo (Japan)
- Kitami Red Cross Hospital, Kitami (Japan)
- National Institute of Radiological Science, Chiba (Japan)
- National Cancer Center, Tokyo (Japan)
Purpose: To review treatment outcomes for stereotactic body radiotherapy (SBRT) in medically operable patients with Stage I non-small-cell lung cancer (NSCLC), using a Japanese multi-institutional database. Patients and Methods: Between 1995 and 2004, a total of 87 patients with Stage I NSCLC (median age, 74 years; T1N0M0, n = 65; T2N0M0, n = 22) who were medically operable but refused surgery were treated using SBRT alone in 14 institutions. Stereotactic three-dimensional treatment was performed using noncoplanar dynamic arcs or multiple static ports. Total dose was 45-72.5 Gy at the isocenter, administered in 3-10 fractions. Median calculated biological effective dose was 116 Gy (range, 100-141 Gy). Data were collected and analyzed retrospectively. Results: During follow-up (median, 55 months), cumulative local control rates for T1 and T2 tumors at 5 years after SBRT were 92% and 73%, respectively. Pulmonary complications above Grade 2 arose in 1 patient (1.1%). Five-year overall survival rates for Stage IA and IB subgroups were 72% and 62%, respectively. One patient who developed local recurrences safely underwent salvage surgery. Conclusion: Stereotactic body radiotherapy is safe and promising as a radical treatment for operable Stage I NSCLC. The survival rate for SBRT is potentially comparable to that for surgery.
- OSTI ID:
- 22054487
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 81, Issue 5; Other Information: Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403
No Clinically Significant Changes in Pulmonary Function Following Stereotactic Body Radiation Therapy for Early- Stage Peripheral Non-Small Cell Lung Cancer: An Analysis of RTOG 0236